Clinical hold disclosureFiled November 5, 2026

REGENXBIO Inc.: SEC 8-K mentions a clinical hold

The filing ↗

REGENXBIO Inc. filed an 8-K with the SEC on November 5, 2026 that mentions a clinical hold. A mention is not always a hold in effect: the filing has the passage.

On the record

Filer
REGENXBIO Inc.
Filed
2026-11-05
Form
8-K
Mentions
clinical hold
Source
SEC EDGAR ↗

The full record

An account shows the passage of the filing that mentions the hold.

What a clinical hold disclosure is

A clinical hold is an FDA order to delay a proposed clinical investigation or to suspend one that is under way. FDA does not publish holds; a listed company discloses one in an 8-K filed with the SEC. A filing can also mention a hold that has been lifted, or one that is only a risk, so the filing itself is the record.

More

Watch REGENXBIO Inc

A free account shows the last 7 days of every record. Pro adds a watchlist: one email when FDA acts on a company you name.

From SEC EDGAR. The record may have changed since it was read.

Approve Suite is not affiliated with FDA or the SEC, or with REGENXBIO Inc.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.